From Dashboards to Decisions: How AI Is Reshaping Pharma Brand Strategy

In the life sciences space, product life cycles are evolving, competitive intensity is increasing and business expectations are rising in lockstep. As a result, brand leaders in pharma are navigating one of the most dynamic, high-pressure commercial environments in the industry’s history.

Over the past decade, organizations have invested heavily in data analytics and dashboards to build a strong foundation for acquiring critical insights. Now, it’s time to use that information to make confident decisions faster and close the gap between having the right data and acting on it.

Enter artificial intelligence (AI)-powered data analytics, which has evolved from a supporting function into the backbone of modern brand strategy and decision-making.^1-3 The question for brand leaders today is not whether to use these tools but how to get enterprise-scale value from them.

Change and competition in the new life sciences landscape

Developments like the Inflation Reduction Act and most-favored-nation policies are reshaping the economics of the product life cycle. At the same time, the dynamics of market access and competitive launches continue to accelerate.^1,2 Additionally, 55% of research and development (R&D) in clinical trials exists in just two therapeutic areas: immunology and oncology. These areas spread R&D costs more effectively, as these products can pursue multiple indications. However, this concentration results in intense competition, with some indications having a dozen or more competing products.

That competitive density, combined with policy-driven economic compression, is creating what amounts to a constant launch mode for many brand teams. The pursuit of multiple indications in rapid succession, or indication stacking, has become one of the most important paths to pulling value into a brand earlier in its life cycle.² A brand manager may be launching as many as a half dozen indications in a two-year window, each with its own need for real-world evidence, messaging, patient support programs and channel strategies. This level of complexity complicates decision-making at scale and can delay time-to-value.

AI-enabled analytics can offer a path to compressing the time between identifying a market trend and deploying a strategic response. Where traditional measurement could leave teams working with performance data that was 12 to 18 months old, new capabilities are bringing that timeline down to weeks or days.^1,2 Forward-thinking decision-making powered by real-time behavioral data is now possible, instead of taking a year to build and implement a strategy and waiting another year to ascertain whether it was effective. The results are faster commercial returns and improved planning cycles.

Turning data volume into a strategic advantage

In a survey of 107 senior commercial leaders, 53% described their data as mostly sufficient to support commercial AI applications, and organizations are actively investing to close remaining gaps.³ The opportunity lies in connecting existing data sources, spanning CRM, field activity, product claims, digital engagement, patient support and market intelligence into a unified, interoperable view.

Traditionally, the industry examined data with great depth but in narrow silos: one therapeutic area, one brand and one channel. Moving forward, breadth will make a more significant difference, as understanding how a prescriber or health system behaves across all brands, in all therapeutic classes and for all their patients is infinitely more useful. This kind of cross-system visibility requires a scale of data that few organizations can access on their own.³

Having the data is only the first step. It needs to be structured, connected and protected. Health care-grade data requires privacy protocols layered into the architecture from the start to ensure compliance as a design feature rather than an afterthought.³ Only then can organizations move from raw, siloed information to the kind of connected intelligence that drives meaningful commercial outcomes.

From mining to farming: A new way to interact with data

The shift from dashboards to AI represents a conceptual leap in how brand teams interact with information. Dashboards are essentially data mining, requiring you to know what you are looking for and drilling in to find it. AI, by contrast, is more like data farming. It brings answers closer to the surface and enables teams to interact with data by asking questions and exploring relationships that may not have been visible before.^1,2

AI is a central part of that value. Processes that once took eight to 12 weeks, such as market access studies, can now be compressed to one to two weeks and are on the verge of taking just days or even minutes.² This kind of acceleration gives brand teams the agility to diagnose and respond to performance dynamics while they are still relevant.

The practical applications of AI span the entire brand life cycle. AI tools can probabilistically map physician adoption curves before activation occurs, enabling brand teams to allocate resources based on predicted behavior rather than historical trends.^1,2 Forecasting, segmentation, messaging and channel mix can evolve in near real time as conditions change. AI provides the consistency and synthesis needed to monitor multiple launches, datasets and leading indicators simultaneously through a unified analytical framework.

Leading organizations are treating AI as institutional infrastructure rather than a collection of individual use cases. A survey of senior commercial leaders found that organizations self-identifying as “AI Advanced” reported higher ROI and broader use-case implementation, with shared traits like centralized governance, cross-functional teams and faster pilot-to-production cycles.³

Building for durability: Leadership, governance and strategic partnerships

AI-enabled brand strategy elevates the role of the brand leader. Rather than coordinating tactical execution across siloed teams, brand managers become orchestrators of data, trade-offs and organizational alignment, enabling them to make higher-value decisions with greater confidence and speed.^1,2

Success in this model depends as much on leadership and operating model choices as on technology. Governance, talent development and cross-functional collaboration are what enable organizations to move beyond pilots to scale AI as a true enterprise capability.³ It also matters whether AI adoption is systematized into the way an organization operates or whether it depends on a small group of champions. The most durable gains come when AI changes the system itself and becomes part of the institutional infrastructure rather than a limited project that could regress if key individuals move on.

Strategic partnerships play a growing role in this evolution. The same survey found that 89% of organizations co-develop AI solutions with external partners and 55% now operate through joint governance structures with shared key performance indicators (KPIs) and road maps.³ The most productive partnerships combine the wide scope of data and domain expertise that commercial AI demands. Technology alone is insufficient. The healthcare space is immensely complex, and the subject matter expertise required to translate information into actionable commercial strategy takes years to build.^2,3

How brand leaders can meet the moment

The commercial environment will continue to evolve rapidly, and brand teams that embrace AI-enabled planning and measurement can make that complexity work for them. The opportunity is in connecting evidence directly to decisions in a way that builds speed, confidence and consistency across the brand life cycle.^1-3

The path forward is about how effectively an organization can embed AI across the brand’s life cycle as an enterprise capability supported by the right data foundation, governance and partnerships. Brands that align teams, incentives and ways of working around AI-enabled decision-making are better positioned to compete and grow in the decade ahead.

Luke Greenwalt is VP and lead, U.S. Thought Leadership & Innovation, at IQVIA.

References

1. Greenwalt L. The brand manager’s perfect storm: why traditional strategies are falling short. IQVIA Blog. October 6, 2025. https://www.iqvia.com/locations/united-states/blogs/2025/10/the-brand-managers-perfect-storm

2. Greenwalt L. How data and AI transform brand strategy. IQVIA Blog. October 8, 2025. https://www.iqvia.com/locations/united-states/blogs/2025/10/how-data-and-ai-transform-brand-strategy

3. Kotakonda S, Awasthi P. AI in life sciences commercialization: strategic insights and practical recommendations from 2025 survey of commercial leaders. IQVIA. August 19, 2025. https://www.iqvia.com/library/white-papers/ai-in-life-sciences-commercialization